Live news related to MAAT PHARMA stock (FR0012634822): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Lyon-based biotech MaaT Pharma has announced the launch of the IMMUNOLIFE clinical trial, a Phase 2 study assessing MaaT033 in combination with cemipl…
MaaT Pharma has disclosed the final results of its phase 3 clinical trial, ARES, assessing MaaT013 for the treatment of refractory acute graft-versus-…
MaaT Pharma, specializing in the development of microbiotic therapies, has announced the successful completion of its capital increase amounting to €9…
MaaT Pharma has announced the launch of a global offering of ordinary shares amounting to approximately €9 million, according to a press release dated…
MaaT Pharma has announced the receipt of funds to support its clinical development programs, following recent agreements with the European Investment …
MaaT Pharma revealed preclinical results for its drug candidate MaaT034 at the annual congress of the Society for Immunotherapy of Cancer (SITC), acco…
MaaT Pharma announced that the results of its Phase 3 study on the Xervyteg treatment will be presented at the ASH 2025 annual congress.
